DE69629949D1 - Aktivierte verbindungen und verfahren zur herstellung und reiningung - Google Patents
Aktivierte verbindungen und verfahren zur herstellung und reiningungInfo
- Publication number
- DE69629949D1 DE69629949D1 DE69629949T DE69629949T DE69629949D1 DE 69629949 D1 DE69629949 D1 DE 69629949D1 DE 69629949 T DE69629949 T DE 69629949T DE 69629949 T DE69629949 T DE 69629949T DE 69629949 D1 DE69629949 D1 DE 69629949D1
- Authority
- DE
- Germany
- Prior art keywords
- pegs
- cleaning
- producing
- activated connections
- molecules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Road Signs Or Road Markings (AREA)
- Thermistors And Varistors (AREA)
- Separation Of Suspended Particles By Flocculating Agents (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/611,918 US5747639A (en) | 1996-03-06 | 1996-03-06 | Use of hydrophobic interaction chromatography to purify polyethylene glycols |
| PCT/US1996/019459 WO1997032607A2 (en) | 1996-03-06 | 1996-12-06 | Activated linkers and methods for making and purifying the same |
| US611918 | 2000-07-07 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69629949D1 true DE69629949D1 (de) | 2003-10-16 |
| DE69629949T2 DE69629949T2 (de) | 2004-07-22 |
Family
ID=24450930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69629949T Expired - Fee Related DE69629949T2 (de) | 1996-03-06 | 1996-12-06 | Aktivierte verbindungen und verfahren zur herstellung und reiningung |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US5747639A (de) |
| EP (1) | EP0906122B1 (de) |
| JP (1) | JP2000506851A (de) |
| AT (1) | ATE249244T1 (de) |
| AU (1) | AU720399B2 (de) |
| CA (1) | CA2248006C (de) |
| DE (1) | DE69629949T2 (de) |
| DK (1) | DK0906122T3 (de) |
| ES (1) | ES2206616T3 (de) |
| PT (1) | PT906122E (de) |
| WO (1) | WO1997032607A2 (de) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| US5932462A (en) * | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5747639A (en) * | 1996-03-06 | 1998-05-05 | Amgen Boulder Inc. | Use of hydrophobic interaction chromatography to purify polyethylene glycols |
| TW555765B (en) | 1996-07-09 | 2003-10-01 | Amgen Inc | Low molecular weight soluble tumor necrosis factor type-I and type-II proteins |
| AU5696198A (en) | 1996-12-06 | 1998-06-29 | Amgen, Inc. | Combination therapy using a tnf binding protein for treating tnf-mediated diseases |
| ATE342729T1 (de) * | 1997-01-15 | 2006-11-15 | Phoenix Pharmacologics Inc | Modifizierter tumor-nekrosefaktor |
| US6448369B1 (en) | 1997-11-06 | 2002-09-10 | Shearwater Corporation | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
| US7642323B2 (en) | 1997-11-06 | 2010-01-05 | Nektar Therapeutics | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
| PT1121382E (pt) | 1998-10-16 | 2006-10-31 | Biogen Idec Inc | Proteinas de fusao do interferao beta e as respectivas utilizacoes |
| EE05201B1 (et) * | 1998-10-16 | 2009-08-17 | Biogen Idec Ma Inc. | Glkoslitud interferoon-beeta, selle kasutamine ja seda sisaldav farmatseutiline kompositsioon, meetod interferoon-beeta-1a aktiivsuse pikendamiseks ja leiutisekohase valgu valmistamiseks |
| US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US6924264B1 (en) | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
| JP2003519478A (ja) | 2000-01-10 | 2003-06-24 | マキシゲン・ホールディングズ・リミテッド | Ｇ−ｃｓｆ結合体 |
| JP2003521930A (ja) | 2000-02-11 | 2003-07-22 | マキシゲン・エイピーエス | 第ＶＩＩ因子または第ＶＩＩａ因子様分子 |
| EE200300213A (et) * | 2000-12-06 | 2003-08-15 | Applied Research Systems Ars Holding N.V. | SARP-1 kasutamine sklerodermia raviks ja/või ennetamiseks |
| MXPA03007619A (es) | 2001-02-27 | 2003-12-04 | Maxygen Aps | Nuevas moleculas similares a interferon beta. |
| EP1441772A2 (de) * | 2001-10-29 | 2004-08-04 | Nektar Therapeutics Al, Corporation | Polymerkonjugate von protein-kinase-c-inhibitoren |
| NZ534708A (en) | 2002-01-18 | 2007-05-31 | Biogen Idec Inc | Polyalkylene glycol with moiety for conjugating biologically active compound |
| WO2004000366A1 (en) | 2002-06-21 | 2003-12-31 | Novo Nordisk Health Care Ag | Pegylated factor vii glycoforms |
| US8129330B2 (en) * | 2002-09-30 | 2012-03-06 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
| NZ541122A (en) * | 2002-12-26 | 2008-09-26 | Mountain View Pharmaceuticals | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
| RS20050502A (en) * | 2002-12-26 | 2007-08-03 | Mountain View Pharmaceuticals Inc., | Polymer conjugates of interferon- beta with enhanced biological potency |
| CN1867581B (zh) | 2003-10-10 | 2012-02-01 | 诺沃挪第克公司 | Il-21衍生物 |
| EP2633866A3 (de) | 2003-10-17 | 2013-12-18 | Novo Nordisk A/S | Kombinationstherapie |
| WO2006069220A2 (en) | 2004-12-22 | 2006-06-29 | Ambrx, Inc. | Modified human growth hormone |
| NZ548255A (en) | 2004-02-02 | 2010-10-29 | Ambrx Inc | Modified human interferon polypeptides and their uses |
| JP2008503217A (ja) | 2004-06-18 | 2008-02-07 | アンブレツクス・インコーポレイテツド | 新規抗原結合ポリペプチド及びそれらの使用 |
| JP2008507280A (ja) | 2004-07-21 | 2008-03-13 | アンブレツクス・インコーポレイテツド | 非天然コードアミノ酸を用いた生合成ポリペプチド |
| MX2007007581A (es) | 2004-12-22 | 2007-07-24 | Ambrx Inc | Composiciones de amino acil-arnt sintetasa y sus usos. |
| NZ555206A (en) | 2004-12-22 | 2010-09-30 | Ambrx Inc | Methods for expression and purification of recombinant human growth hormone |
| KR101224781B1 (ko) | 2004-12-22 | 2013-01-21 | 암브룩스, 인코포레이티드 | 비천연적으로 코딩된 아미노산을 포함하는 인간 성장호르몬의 조제물 |
| SG165353A1 (en) | 2005-06-03 | 2010-10-28 | Ambrx Inc | Improved human interferon molecules and their uses |
| ES2553160T3 (es) | 2005-06-17 | 2015-12-04 | Novo Nordisk Health Care Ag | Reducción y derivatización selectivas de proteínas Factor VII transformadas por ingeniería que comprenden al menos una cisteína no nativa |
| NZ565294A (en) | 2005-08-18 | 2010-06-25 | Ambrx Inc | Compositions of tRNA and uses thereof |
| JP2009520949A (ja) | 2005-11-16 | 2009-05-28 | アンブルックス，インコーポレイテッド | 非天然アミノ酸を含んでいる組成物および方法 |
| CN101500614B (zh) | 2006-02-28 | 2011-08-10 | 雷迪实验室（欧洲）有限公司 | 制备聚乙二醇碳酸酯的方法 |
| CN101484576A (zh) | 2006-05-24 | 2009-07-15 | 诺沃-诺迪斯克保健股份有限公司 | 具有延长的体内半寿期的因子ix类似物 |
| CN101541955B (zh) | 2006-09-08 | 2016-09-28 | Ambrx公司 | 用于脊椎动物细胞的杂合抑制tRNA |
| PT2064333E (pt) | 2006-09-08 | 2014-06-09 | Ambrx Inc | Supressor híbrido arnt para células de vertebrados |
| EP2615108B1 (de) | 2006-09-08 | 2016-10-26 | Ambrx, Inc. | Modifiziertes humanes Plasmapolypeptid oder Fc-Gerüste und deren Verwendungen |
| WO2008101311A1 (en) * | 2007-02-22 | 2008-08-28 | Biovectra Inc. | Process for purification of water soluble polymers |
| KR20160121601A (ko) | 2007-03-30 | 2016-10-19 | 암브룩스, 인코포레이티드 | 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도 |
| MX2009011870A (es) | 2007-05-02 | 2009-11-12 | Ambrx Inc | Polipeptidos de interferon beta modificados y usos de los mismos. |
| NZ603812A (en) | 2007-11-20 | 2014-06-27 | Ambrx Inc | Modified insulin polypeptides and their uses |
| CA2712606A1 (en) | 2008-02-08 | 2009-08-13 | Ambrx, Inc. | Modified leptin polypeptides and their uses |
| ES2654387T3 (es) | 2008-07-23 | 2018-02-13 | Ambrx, Inc. | Polipéptidos G-CSF bovinos modificados y sus usos |
| DK2342223T3 (en) | 2008-09-26 | 2017-07-24 | Ambrx Inc | Modified animal erythropoietin polypeptides and their uses |
| EA201170493A1 (ru) | 2008-09-26 | 2011-10-31 | Амбркс, Инк. | Микроорганизмы и вакцины, зависимые от репликации неприродных аминокислот |
| CN107674121A (zh) | 2009-12-21 | 2018-02-09 | Ambrx 公司 | 经过修饰的牛促生长素多肽和其用途 |
| KR20120123365A (ko) | 2009-12-21 | 2012-11-08 | 암브룩스, 인코포레이티드 | 변형된 돼지 소마토트로핀 폴리펩티드 및 이의 용도 |
| JP6148013B2 (ja) | 2010-03-05 | 2017-06-14 | リグショスピタレト | 補体活性化のキメラ抑制分子 |
| JP2013528374A (ja) | 2010-05-10 | 2013-07-11 | パーシード セラピューティクス リミテッド ライアビリティ カンパニー | Ｖｌａ４のポリペプチド阻害剤 |
| US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
| MA34521B1 (fr) | 2010-08-17 | 2013-09-02 | Ambrx Inc | Polypeptides de relaxine modifiés et leurs utilisations |
| AR083006A1 (es) | 2010-09-23 | 2013-01-23 | Lilly Co Eli | Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas |
| EP2726502A1 (de) | 2011-07-01 | 2014-05-07 | Bayer Intellectual Property GmbH | Relaxin-fusionspolypeptide und ihre verwendung |
| JP6498600B2 (ja) | 2012-06-08 | 2019-04-10 | ストロ バイオファーマ インコーポレーテッド | 部位特異的な非天然アミノ酸残基を含む抗体、その調製方法、及びその使用方法 |
| EP2863955B1 (de) | 2012-06-26 | 2016-11-23 | Sutro Biopharma, Inc. | Modifizierte fc-proteine mit nichtnatürlichen ortsspezifische aminosäureresten, konjugate daraus, verfahren zu deren herstellung und verfahren zu deren verwendung |
| US9395468B2 (en) | 2012-08-27 | 2016-07-19 | Ocular Dynamics, Llc | Contact lens with a hydrophilic layer |
| WO2014036492A1 (en) | 2012-08-31 | 2014-03-06 | Sutro Biopharma, Inc. | Modified amino acids comprising an azido group |
| JP2016518311A (ja) * | 2013-03-08 | 2016-06-23 | ユニヴァーシティー オブ サザン カリフォルニア | ビニルスルホン系１８ｆ標識化組成物ならびにその方法およびその使用 |
| EP3019522B1 (de) | 2013-07-10 | 2017-12-13 | Sutro Biopharma, Inc. | Antikörper mit mehreren ortsspezifischen nichtnatürlichen aminosäureresten, verfahren zu deren herstellung und verfahren zu deren verwendung |
| WO2015054658A1 (en) | 2013-10-11 | 2015-04-16 | Sutro Biopharma, Inc. | Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use |
| EP3570093B1 (de) | 2013-11-15 | 2021-09-15 | Tangible Science, Inc. | Kontaktlinse mit hydrophiler schicht |
| SMT202100388T1 (it) | 2014-10-24 | 2021-09-14 | Bristol Myers Squibb Co | Polipeptidi fgf-21 modificati e loro usi |
| US10525170B2 (en) | 2014-12-09 | 2020-01-07 | Tangible Science, Llc | Medical device coating with a biocompatible layer |
| EP3580232B1 (de) | 2017-02-08 | 2023-09-20 | Bristol-Myers Squibb Company | Modifizierte relaxin-polypeptide mit einem pharmakokinetischen verstärker und deren verwendungen |
| AU2019337610A1 (en) | 2018-09-11 | 2021-05-06 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and their uses |
| EP3867265A1 (de) | 2018-10-19 | 2021-08-25 | Ambrx, Inc. | Interleukin-10 -polypeptid-konjugate, dimere davon und ihre verwendungen |
| US20220226488A1 (en) | 2019-02-12 | 2022-07-21 | Ambrx, Inc. | Compositions containing, methods and uses of antibody-tlr agonist conjugates |
| CN114555204A (zh) | 2019-09-10 | 2022-05-27 | 皮尔斯生物科技有限公司 | 样品制备组合物、装置、系统和方法 |
| IL296099A (en) | 2020-03-11 | 2022-11-01 | Ambrx Inc | Interleukin-2 polypeptide conjugates and methods of use thereof |
| JP2023538071A (ja) | 2020-08-20 | 2023-09-06 | アンブルックス，インコーポレイテッド | 抗体－ｔｌｒアゴニストコンジュゲート、その方法及び使用 |
| IL307282A (en) | 2021-04-03 | 2023-11-01 | Ambrx Inc | Antidote conjugates against HER2 and their applications |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989004203A1 (en) * | 1987-11-10 | 1989-05-18 | North Carolina State University | Chromatography apparatus and method and material for making the same |
| US5094960A (en) * | 1988-10-07 | 1992-03-10 | New York Blood Center, Inc. | Removal of process chemicals from labile biological mixtures by hydrophobic interaction chromatography |
| US5349052A (en) * | 1988-10-20 | 1994-09-20 | Royal Free Hospital School Of Medicine | Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor |
| US5645717A (en) * | 1989-01-13 | 1997-07-08 | Bio-Rad Laboratories, Inc. | Hydrophobic polymers from water-soluble monomers and their use as chromatography media |
| IL95031A (en) * | 1989-07-18 | 2007-03-08 | Amgen Inc | Method for the production of a human recombinant tumor necrosis factor inhibitor |
| US6552170B1 (en) * | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| CA2106079C (en) * | 1991-03-15 | 2000-04-25 | Robert C. Thompson | Pegylation of polypeptides |
| WO1993001498A1 (en) * | 1991-07-04 | 1993-01-21 | Immunodex K/S | Water-soluble, polymer-based reagents and conjugates comprising moieties derived from divinyl sulfone |
| US5424063A (en) * | 1992-01-09 | 1995-06-13 | The Dow Chemical Company | Narrow poly- and mono-dispersed anionic oligomers, and their uses, formulations and process |
| ZA933926B (en) * | 1992-06-17 | 1994-01-03 | Amgen Inc | Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules |
| EP0622394A1 (de) * | 1993-04-30 | 1994-11-02 | S.A. Laboratoires S.M.B. | Umkehrbare Modifikation von Verbindungen, Schwefel enthaltend, mit Polyalkylengycol und ihre Verwendung |
| JP3583429B2 (ja) * | 1993-07-16 | 2004-11-04 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 疎水クロマトグラフィーのための分離剤 |
| US5446090A (en) * | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| US5476643A (en) * | 1993-11-19 | 1995-12-19 | Bernel Chemical Co. | Method of dispersing micronized TIo2, ZnO and other pigments |
| DE19517848A1 (de) * | 1995-05-16 | 1996-11-21 | Merck Patent Gmbh | Fluorhaltige Benzoylguanidine |
| US5747639A (en) * | 1996-03-06 | 1998-05-05 | Amgen Boulder Inc. | Use of hydrophobic interaction chromatography to purify polyethylene glycols |
-
1996
- 1996-03-06 US US08/611,918 patent/US5747639A/en not_active Expired - Lifetime
- 1996-12-06 WO PCT/US1996/019459 patent/WO1997032607A2/en active IP Right Grant
- 1996-12-06 AT AT96944251T patent/ATE249244T1/de not_active IP Right Cessation
- 1996-12-06 JP JP9531747A patent/JP2000506851A/ja active Pending
- 1996-12-06 DE DE69629949T patent/DE69629949T2/de not_active Expired - Fee Related
- 1996-12-06 EP EP96944251A patent/EP0906122B1/de not_active Expired - Lifetime
- 1996-12-06 ES ES96944251T patent/ES2206616T3/es not_active Expired - Lifetime
- 1996-12-06 PT PT96944251T patent/PT906122E/pt unknown
- 1996-12-06 AU AU14108/97A patent/AU720399B2/en not_active Ceased
- 1996-12-06 CA CA002248006A patent/CA2248006C/en not_active Expired - Fee Related
- 1996-12-06 DK DK96944251T patent/DK0906122T3/da active
-
1997
- 1997-09-18 US US08/936,478 patent/US5935564A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| PT906122E (pt) | 2003-12-31 |
| WO1997032607A2 (en) | 1997-09-12 |
| AU720399B2 (en) | 2000-06-01 |
| DE69629949T2 (de) | 2004-07-22 |
| ATE249244T1 (de) | 2003-09-15 |
| CA2248006A1 (en) | 1997-09-12 |
| ES2206616T3 (es) | 2004-05-16 |
| EP0906122B1 (de) | 2003-09-10 |
| US5935564A (en) | 1999-08-10 |
| WO1997032607A3 (en) | 1997-11-13 |
| AU1410897A (en) | 1997-09-22 |
| EP0906122A2 (de) | 1999-04-07 |
| JP2000506851A (ja) | 2000-06-06 |
| CA2248006C (en) | 2002-05-28 |
| DK0906122T3 (da) | 2004-01-19 |
| US5747639A (en) | 1998-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69629949D1 (de) | Aktivierte verbindungen und verfahren zur herstellung und reiningung | |
| DE69106815D1 (de) | Verfahren zur Herstellung von veränderten Kohlenstoffmolekularsieben zur Gastrennung. | |
| DE69630570D1 (de) | Verfahren zur Herstellung von gestützten Membranen | |
| DE69427144D1 (de) | Verfahren und System zur Herstellung von Ethanol aus Mikroalgen | |
| ATE381963T1 (de) | Verfahren zur herstellung von gereinigten partikeln | |
| ATE278785T1 (de) | Neues verfahren zur gewinnung und reinigung von fusionsproteinen | |
| ATE226960T1 (de) | Verfahren zur herstellung von cardiodilatin- fragmenten, hochgereinigte cardiodilatin- fragmente und zwischenprodukte zu deren herstellung | |
| ATE214612T1 (de) | Biologisch aktive substanzen, verfahren zur herstellung und sie enthaltende zusammensetzungen | |
| ATE135936T1 (de) | Vorrichtung und verfahren zur entfernung von kohlenwasserstoffen aus gasströmen | |
| ATE278390T1 (de) | Verfahren zur herstellung von arzneistoffpartikeln | |
| DE69107992D1 (de) | Verfahren zur elektrolytischen Herstellung von Ozon und Vorrichtung dazu. | |
| DE69407272D1 (de) | Verfahren zum reinigen von 20 cs)-camptothecin | |
| DE59603541D1 (de) | Verfahren zur Reinigung von Bisphenol-A | |
| NZ308862A (en) | Method for purifying thrombopoietin (tpo) | |
| DE68915664D1 (de) | Verfahren zur Herstellung von Rohreinheiten. | |
| DE69502313D1 (de) | Verfahren zur biologischen Reinigung von Gasströmen | |
| ATE210695T1 (de) | Verfahren zur herstellung von poly(diorganosiloxanen), mischungen, enthaltend diese poly(diorganosiloxane) und deren verwendung | |
| DE59102062D1 (de) | Verfahren zur biologischen Reinigung von Abluftströmen. | |
| DE69531308D1 (de) | Verfahren zur Herstellung von gereinigten papillomavirus Proteinen | |
| DE59305117D1 (de) | Verfahren zur Herstellung von Ameisensäure aus Kohlenmonoxid und Wasser | |
| DE69221841D1 (de) | Verfahren zur Herstellung von gereinigtem Xanthangummi | |
| DE59603826D1 (de) | Verfahren zur kontinuierlichen Herstellung von macrocyclischen Verbindungen | |
| DE69630038D1 (de) | Verfahren zur herstellung und aufreinigung von enzymen | |
| DE69725580D1 (de) | Prozess zur herstellung von aza zyclohexapeptide | |
| DE59506870D1 (de) | Verfahren zur Herstellung von Polyamiden auf Basis von alpha,omega-Dinitrilen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |